Effect of fluvastatin on levels of matrix metalloproteinases-9 and tissue factor in patients with acute coronary syndrome
- VernacularTitle:氟伐他汀对急性冠状动脉综合征患者基质金属蛋白酶-9及组织因子的影响
- Author:
Qingbin XU
;
Meihua JIN
;
Li XUE
- Publication Type:Journal Article
- Keywords:
Acute coronary syndrome;
Fluvastatin;
Matrix metalloproteinase-9;
Tissue factor
- From:
Clinical Medicine of China
2008;24(11):1089-1092
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the levels of matrix metalloproteinases-9 (MMP-9) and tissue factor (TF) as well as blood lipid in patients with acute coronary syndrome (ACS) ,and to study the effect of Fluvastatin on levels of serum MMP- 9 and plasma TF. Methods 40 patients with ACS were selected (including 20 patients with AMI and 20 patients with UAP) ,20 stable angina patients (SAP) and 13 patients without coronary heart dis-ease as control group. 40 patients with ACS were randomly assigned to the Fluvastatin group (n = 20) and the rou-tine group (n = 20) in this study. The MMP - 9 and TF were detected on admission and after 2 weeks treatment. Re-suits The levels of MMP-9 and TF were significantly higher in ACS group than that of SAP and control group (P < 0.001 ,P < 0.05) ,which were elevated in AMI group compared with that of UAP group (P < 0.05). The levels of cholesterol (TC) ,low density Lipoprotein (LDL - C) ,MMP- 9,TF decreased significantly at two weeks after treat-ment in fluvastatin group (P < 0.05), but no significant changes were observed in the routine group (P > 0.05). The change of MMP 9, TF and blood lipid was not related in fluvastatin group (P > 0.05). Conclusion Serum MMP-9 and plasma TF in ACS patients are significantly elevated and fluvastatin decreases the levels of MMP-9 and TF after two weeks treatment,so it may be benefit to atheroaclerotic plaque stabilization and prohihit thrombosis for-marion, and this is not related to regulation of blood lipid.
